Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease

BackgroundCachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD.MethodsWe analyzed 356 of 526 patients with CLD who had complete c...

詳細記述

書誌詳細

主要な著者:	Takatsugu Tanaka, Goki Suda, Masatsugu Ohara, Osamu Maehara, Tomoka Yoda, Qingjie Fu, Zijian Yang, Naohiro Yasuura, Akimitsu Meno, Takashi Sasaki, Risako Kohya, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Takuya Sho, Shunsuke Ohnishi, Naoya Sakamoto
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2026-02-01
シリーズ:	Frontiers in Nutrition
主題:	biomarker cachexia chronic liver disease fibroblast growth factor liver cirrhosis
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fnut.2026.1730695/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!